CD33 and acute myeloid leukemia: In 2014, Pizzitola compared the cytotoxicity of CD123 and CD33 CAR on AML, and find that no difference in anti-leukemic activity, yet CD33 CAR appeared to have stronger cytotoxicity on normal HSPCs compared with CD123 CAR (103).